ARTICLE | Clinical News

Tasimelteon: Phase III data

June 30, 2008 7:00 AM UTC

In a double-blind Phase III trial in 322 patients, both doses of tasimelteon (20 and 50 mg) met the primary endpoint of a significant improvement in LPS on nights 1 and 8 vs. placebo. Mean LPS improve...